Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Lithium & Battery Tech ETF (LIT) vs Novavax Inc (NVAX) Price & Performance

Global X Lithium & Battery Tech ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Global X Lithium & Battery Tech ETF vs Novavax Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.77 (market cap $1.45B), while Novavax Inc trades at $13.01 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Global X Lithium & Battery Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and Novavax Inc for 59 Days on average.

LITNVAX
Market Cap
$1.45B$1.82B
Volume
89,3926,198,505
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$91.62$12.56
52-Week Low
$53.92$6.22
Typical Hold Time
56 Days59 Days
Enterprise Value
—$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Lithium & Battery Tech ETF

LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.

Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LIT

No sentiment data available yet.

NVAX
55% Buy45% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Global X Lithium & Battery Tech ETF

LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.

Read more on LIT →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →